FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 02/2022”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Life Sciences sector.
As of the tip of February 2022 we determine the next present VC traits in Europe:
- In 2022, total Life Sciences funding has reached EUR 1,661m up to now
- Prime 5 Offers exceed EUR 60m every, largest transaction amounted to EUR 125m in Affected person21 (Germany)
- Curie Capital (Netherlands) dominates the Prime 5 Buyers (by deal quantity), adopted by Dompé (Italy) and Casdin Capital (United States)
- The Biotech sector obtained 42% of the entire funding quantity (+7% factors in comparison with the earlier month)
- Oncology dominates as the highest indication of the Biotechnology sector
To entry the complete report, please click on right here.
By Dr. Mathias Schott and Sebastian Sommer